C
Christoph Funk
Researcher at Hoffmann-La Roche
Publications - 50
Citations - 2889
Christoph Funk is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Physiologically based pharmacokinetic modelling & In vivo. The author has an hindex of 25, co-authored 49 publications receiving 2611 citations. Previous affiliations of Christoph Funk include University of Zurich & University of Bern.
Papers
More filters
Journal ArticleDOI
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Karin Fattinger,Karin Fattinger,Karin Fattinger,Christoph Funk,Christoph Funk,Christoph Funk,Michael Pantze,Michael Pantze,Michael Pantze,Cornelia Weber,Cornelia Weber,Cornelia Weber,Jürg Reichen,Jürg Reichen,Jürg Reichen,Bruno Stieger,Bruno Stieger,Bruno Stieger,Peter J. Meier,Peter J. Meier,Peter J. Meier +20 more
TL;DR: In this study, inhibition of the hepatocanalicular bile salt export pump (rodents, Bsep; humans, BSEP ABCB11) could account for bosentan‐induced liver injury.
Journal ArticleDOI
Cholestatic Potential of Troglitazone as a Possible Factor Contributing to Troglitazone-Induced Hepatotoxicity: In Vivo and in Vitro Interaction at the Canalicular Bile Salt Export Pump (Bsep) in the Rat
TL;DR: A high accumulation potential was observed for trog litazone sulfate in rat liver tissue, indicating that the hepatobiliary export of this conjugated metabolite might represent a rate-limiting step in the overall elimination process of troglitazone.
Journal ArticleDOI
Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3
TL;DR: The results indicate that the in vitro engineered systems can not always predict the behavior in more complex systems such as freshly isolated primary hepatocytes, and selection of substrate, substrate concentration, and in vitro transport system are critical for the conduct of in vitro interaction studies involving individual liver OATP carriers.
Journal ArticleDOI
Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate
Christoph Funk,Michael Pantze,Linda Jehle,Christiane Ponelle,Gerd Scheuermann,Mirjana Lazendic,Rodolfo Gasser +6 more
TL;DR: In this paper, the cholestatic potential of troglitazone and its major metabolite, Troglitaxone sulfate, has been investigated in rats.
Journal ArticleDOI
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria
Joe Bentz,Michael P. O'Connor,Dallas Bednarczyk,Joann Coleman,Caroline A. Lee,Johan E. Palm,Anne Pak,Elke S Perloff,Eric L. Reyner,Praveen Balimane,Marie Brännström,Xiaoyan Chu,Christoph Funk,Ailan Guo,Imad Hanna,Krisztina Herédi-Szabó,Kathleen M. Hillgren,Libin Li,Evelyn Hollnack-Pusch,Masoud Jamei,Xuena Lin,Andrew K Mason,Sibylle Neuhoff,Aarti Patel,Lalitha Podila,Emile Plise,Ganesh Rajaraman,Laurent Salphati,Eric Sands,Mitchell E. Taub,Jesse Taur,Dietmar Weitz,Heleen M. Wortelboer,Cindy Q. Xia,Guangqing Xiao,Jocelyn Yabut,Tetsuo Yamagata,Lei K. Zhang,Harma Ellens +38 more
TL;DR: Ellens et al. as discussed by the authors established a P-glycoprotein IC50 working group with 23 participating pharmaceutical and contract research laboratories and one academic institution to assess interlaboratory variability in P-gp IC50 determinations.